SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2020 / Cilt: 45 - Sayı: 6

Therapeutic agents currently employed against Covid-19: an effort to control the pandemic

[Covid-19’a Karşi Kullanilan Terapötik Ajanlar: Pandemi Kontrolü İçin Bir Çalişma]

Iván Antonio GARCİA MONTALVO
Diana MANTİAS PEREZ
Alma Dolores PEREZ SANTİAGO
Marco Antonio SANCHEZ MEDİNA
Pages
651–658
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the absence of treatment forthis virus, there is an urgent need to find alternative methodsto control the spread of the disease, so we haveconducted an online search for all treatment options relatedto coronavirus infections, as well as some infectionsdue to viruses, general treatments, specific coronavirustreatments and antiviral treatments should be useful in thefight against COVID-19, the therapeutic agents evaluatedincluded chloroquine/hydroxychloroquine, lopinavir/ritonavir, tocilizumab, ribavirin, interferons, nelfinavir,ivermectin, monoclonal antibodies and convalescentplasma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract: The disease caused by the new coronavirus(COVID-19) is characterized by fever and cough, in additionto affecting the lower respiratory tract and being associatedwith age, comorbidities and a weakened immune system.Lymphopenias occur in severe cases and an excessiveproduction of inflammatory cytokines, which would explainthe role of the hyperinflammatory response in thepathogenesis of COVID-19.
📊
Key Findings & Data:Abstract: The disease caused by the new coronavirus(COVID-19) is characterized by fever and cough, in additionto affecting the lower respiratory tract and being associatedwith age, comorbidities and a weakened immune system.Lymphopenias occur in severe cases and an excessiveproduction of inflammatory cytokines, which would explainthe role of the hyperinflammatory response in thepathogenesis of COVID-19.
💡
Conclusion & Impact:In the absence of treatment forthis virus, there is an urgent need to find alternative methodsto control the spread of the disease, so we haveconducted an online search for all treatment options relatedto coronavirus infections, as well as some infectionsdue to viruses, general treatments, specific coronavirustreatments and antiviral treatments should be useful in thefight against COVID-19, the therapeutic agents evaluatedincluded chloroquine/hydroxychloroquine, lopinavir/ritonavir, tocilizumab, ribavirin, interferons, nelfinavir,ivermectin, monoclonal antibodies and convalescentplasma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Abstract: The disease caused by the new coronavirus(COVID-19) is characterized by fever and cough, in additionto affecting the lower respiratory tract and being associatedwith age, comorbidities and a weakened immune system.Lymphopenias occur in severe cases and an excessiveproduction of inflammatory cytokines, which would explainthe role of the hyperinflammatory response in thepathogenesis of COVID-19. In the absence of treatment forthis virus, there is an urgent need to find alternative methodsto control the spread of the disease, so we haveconducted an online search for all treatment options relatedto coronavirus infections, as well as some infectionsdue to viruses, general treatments, specific coronavirustreatments and antiviral treatments should be useful in thefight against COVID-19, the therapeutic agents evaluatedincluded chloroquine/hydroxychloroquine, lopinavir/ritonavir, tocilizumab, ribavirin, interferons, nelfinavir,ivermectin, monoclonal antibodies and convalescentplasma.

Özet

Yeni koronavirüsün (COVID-19) neden olduğu hastalık, alt solunum yolunu etkilemesine ve yaş, komorbiditeler ve zayıflamış bağışıklık sistemi ile ilişkili olmasının yanı sıra ateş ve öksürük ile karakterizedir. Lenfopeniler şiddetli vakalarda ortaya çıkar ve aşırı inflamatuar sitokin üretimi, COVID-19’un patogenezinde hiperinflamatuar yanıtın rolünü açıklar. Bu virüs için tedavi olmadığında, hastalığın yayılmasını kontrol etmek için alternatif yöntemler bulmaya acil ihtiyaç vardır, bu nedenle koronavirüs enfeksiyonlarıyla ilgili tüm tedavi seçenekleri ve virüslere bağlı bazı enfeksiyonlar için çevrimiçi bir araştırma yaptık. COVID-19 ile mücadelede genel tedaviler, spesifik koronavirüs tedavileri ve antiviral tedaviler yararlı olmalıdır; değerlendirilen terapötik ajanlar arasında klorokin / hidroksiklorokin, lopinavir/ ritonavir, tocilizumab, rivabirin, interferonlar, nelfinavir, ivermektin, monoklonal antikorlar ve iyileşen plazma yer almaktadır.

🔖

Cite This Article

MONTALVO, I. A. G., PEREZ, D. M., SANTİAGO, A. D. P., MEDİNA, M. A. S. (2022). Therapeutic agents currently employed against Covid-19: an effort to control the pandemic. Türk Biyokimya Dergisi, Cilt: 45 - Sayı: 6, 651–658. https://ajindex.com/articles/620741

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 2020;38:10–8
  2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc 2020;323:1061–9
  3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus– infected pneumonia. N Engl J Med 2020;382:1199–207
  4. Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses 2020;12:135
  5. WHO. World Health Organization [Internet]. Situation reports 2020:1 p. Available from: https://covid19.who.int/ [Cited 14 Sep 2020]
  6. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;2600:19–21
  7. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020;172:577–82
  8. Wong T-W, Tam W. Estimating SARS incubation period. Emerg Infect Dis 2004;10:1503–4
  9. Yang Y, Sugimoto JD, Halloran ME, Basta NE, Chao DL, Matrajt L, et al. The transmissibility and control of pandemic influenza A (H1N1) virus. Science 2009;326:729–33
  10. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260–3
  11. Bosch BJ, Bartelink W, Rottier PJM. Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. J Virol 2008;82:8887–90
  12. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir Res 2020;176:104742
  13. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020;14:185–92
  14. Gao QY, Chen YX, Fang JY. 2019 novel coronavirus infection and gastrointestinal tract. J Dig Dis 2020;21:125–6
  15. Fehr AR, Perlman S. Coronav